Virios therapeutics announces positive data demonstrating improvement in multiple long-covid symptoms following treatment with a combination of valacyclovir and celecoxib in an exploratory, open-label, proof of concept study

Atlanta, july 17, 2023 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”), today announced that female patients diagnosed with long-covid illness, otherwise known as post-acute sequelae of covid-19 infection (“pasc”), exhibited clinically and statistically significant improvements in fatigue, pain, and symptoms of autonomic dysfunction and general well-being related to long-covid when treated open-label with a combination of valacyclovir and celecoxib (“val/cel”) for 14 weeks, as compared to a control cohort of female long-covid patients matched by age, gender and length of illness and treated with routine care. the statistically significant improvements in pasc symptoms and general health status were particularly encouraging given that the mean duration of long-covid illness was two years for both the treated and control cohort prior to enrollment in this trial.
VIRI Ratings Summary
VIRI Quant Ranking